Drug Trial Radar · NCT06341335
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Jun 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
506
Planned (sponsor's estimate)
Start
Jun 19, 2024
Primary completion
Nov 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Apr 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, multicenter, double-blind, phase 3 study will evaluate the efficacy and safety of the combination of cadonilimab (AK104) and pulocimab (AK109) and paclitaxel compared with paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma who failed first-line immunochemotherapy.
Conditions
- Gastric and Gastroesophageal Junction Adenocarcinoma
Interventions
cadonilimabDrug
iv, q3w
pulocimabDrug
iv, q3w
paclitaxelDrug
iv, q3w
placeboDrug
iv, q3w
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) assessed by blinded independent central review (BICR)Time frame: Up to 2 years
- Overall survival (OS)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital & Institute
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.